Floatz logo

Ixabepilone

Breast Carcinoma

Xijing HospitalSmall moleculePhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
81/ 100

Competitive context

209 Active assets in the Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Trastuzumab
SWOG Cancer Research Network
Phase 4BBB
Zoledronate
Washington University School of Medicine
Phase 4BBB
Trastuzumab Deruxtecan
SWOG Cancer Research Network
Phase 4BBB
Tamoxifen
Dartmouth-Hitchcock Medical Center
Phase 4BBB
Pertuzumab
SWOG Cancer Research Network
Phase 3BBB

View all 50 →

Same molecule, other indications

Ixabepilone is also rated in:

ovarian carcinomaDormant
BB
Indicative · Phase 2
68 / 100
View asset →
metastatic neoplasmDormant
BB
Indicative · Phase 3
66 / 100
View asset →
breast cancerDormant
BB
Indicative · Phase 3
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →